Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB014 vs Lucentis in nAMD
NCT05461339Phase 3Active, not recruiting
- Sponsor
- TOT Biopharm
- Start
- Jun 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by TOT Biopharm. Primary endpoint: Change in Best Corrected Visual Acuity at 52 weeks. Started Jun 2022; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05461339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461339.